2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Breast
1
Conditions
Breast Neoplasms
228
Neoplasm Metastasis
19
Neoplasms
9
Breast Neoplasms, Male
7
Breast Diseases
7
Ovarian Neoplasms
4
Carcinoma, Intraductal, Noninfiltrating
4
Recurrence
3
Obesity
3
Endometrial Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Breast Carcinoma In Situ
3
Breast Cancer Metastatic
3
Advanced Breast Cancer
3
Prostatic Neoplasms
2
Neoplasms by Site
2
Multiple Endocrine Neoplasia Type 1
2
Carcinoma, Renal Cell
2
Bulbo-Spinal Atrophy, X-Linked
2
Arthralgia
2
Vitamin D Deficiency
1
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Tuberous Sclerosis
1
Triple Negative Breast Neoplasms
1
Thoracic Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sleep Wake Disorders
1
Skin Diseases
1
Sexuality
1
Interventions
Carboplatin
12
Pemetrexed
8
pembrolizumab
4
Paclitaxel
4
Cisplatin
4
durvalumab
3
Radiosurgery
3
Gemcitabine
3
selpercatinib
2
pralsetinib
2
osimertinib
2
camrelizumab
2
atezolizumab
2
Docetaxel
2
taletrectinib
1
repotrectinib
1
motexafin gadolinium
1
exemestane
1
entinostat
1
ceralasertib
1
cemiplimab
1
belinostat
1
belagenpumatucel L
1
alectinib
1
Vinorelbine
1
Tyrosine Kinase Inhibitors
1
TNFSF10 protein, human
1
Radiotherapy
1
Platinum Compounds
1
Patient Reported Outcome Measures
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Bronchogenic
×
exemestane
×
Clear all
NCT01594398
2021-11-19
ENCORE110
Syndax Pharmaceuticals
Phase 1
Completed
14 enrolled